PF-07832837 is under clinical development by Pfizer and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication ...

BRUSSELS, January 6. /TASS/. The court of the Belgian city of Liege will hold a session to consider whether President of the European Commission (EC) Ursula von der Leyen has legal immunity against ...

These four S&P 500 stocks pay 6% and higher dividends, have Buy ratings at top Wall Street firms, and are offering excellent ...

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

Pfizer (NYSE: PFE) stock investors are curious about the valuation and prospects for the healthcare company. *Stock prices ...

The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

Aetna is taking legal action against Pfizer, Novartis, Teva Pharmaceuticals and others, saying the list of drugmakers ...

Another $50,000 from tobacco giant Altria last month brings money raised to expand the Republican Party of Kentucky ...

Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this ...

This is old news, the FDA-spinned student research is late by over a year. Other independent scientists and labs had made this discovery.

Pfizer (NYSE: PFE) is an interesting healthcare company with excellent prospects for cash flow growth. Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day.

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...